Reimagining the Water Bottle: Jabil Packaging Solutions Launches VITTEL® Hybrid Bottle
9.6.2021 15:47:00 EEST | Business Wire | Press release
Jabil Packaging Solutions, a division of Jabil Inc. (NYSE: JBL), today launched its latest packaging prototype: the Eco.bottle® product platform for VITTEL®, a leading mineral water brand in Europe from the water division of Nestlé. Designed for scalability by a team including Ecologic Brands, acquired by Jabil earlier this year, the VITTEL® hybrid bottle leverages paper and plastic components, resulting in a plastic reduction of more than 50 percent compared to VITTEL®’s current 1-liter bottle. Moreover, this bottle features a patent-pending, first-of-its-kind tear strip, enabling easy separation of the paper and plastic components for an efficient, consumer-friendly recycling experience. This breakthrough innovation is comprised of 100 percent recycled paper and plastic materials, creating a circular system from readily available, high-volume waste streams. Consumer testing in Europe will begin in June and the bottle will be showcased to the media during the upcoming Tour de France, taking place June 26, 2021 through July 18, 2021.
“True innovation in sustainable packaging requires a holistic view of the product that goes beyond aesthetics, material selection and design features,” said Julie Corbett, senior business unit director of Jabil and founder of Ecologic Brands. “Our goal is to innovate around the entire life cycle of the bottle, not only to decrease the use of plastic. That’s why the Eco.bottle® product platform is engineered to drive plastic reduction, improve carbon footprint and optimize the consumer recycling experience.”
Constructed of 80 percent paper and only 20 percent recycled plastic (cap included), the VITTEL® hybrid bottle’s two-shell system, enabled by interlocking paper tabs, allows for nesting during transit and warehousing. This eliminates extra space in the supply chain and has the potential to lessen the amount of trucks needed for delivery by 50-60 percent.
The VITTEL® hybrid bottle project began in 2020; in less than one year, VITTEL® and Jabil have successfully delivered one of the world’s first hybrid water bottles. VITTEL’s deep knowledge of mineral water bottling helped achieve the thinnest 1-liter plastic liner in the market today, which uses just 9.2g of recycled plastic. Jabil’s conversion technology and expertise enabled the fabrication of an elegant and functional outer shell made of certified Forest Stewardship Council reclaimed and recycled material.
“It’s no longer enough for CPG companies to say they’ve reduced their waste. They now also need compelling solutions for repurposing that waste,” said Jason Paladino, senior vice president of Jabil and CEO of Jabil Packaging Solutions. “Jabil’s Box-to-Bottle® manufacturing platform allows us to take our customers' waste and incorporate it into our manufacturing process within our facilities in Manteca, California and Tortosa, Spain. This fully accountable and traceable manufacturing platform provides forward-thinking brands like VITTEL® with unparalleled visibility into the circularity of their products.”
“Thanks to Jabil’s innovative Eco.bottle® product platform, the VITTEL® hybrid bottle is the result of a journey launched several years ago to explore options for drastically reducing the proportion of plastic in our packaging,” said Laure Goutagneux, VITTEL® marketing director. “We are thrilled with the results of our collaboration, including a plastic reduction of 50 percent when compared to our current lightweight bottles.”
About Jabil:
Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005197/en/
Contact information
Media Contact
Michelle Smith
VP Communications & Brand Strategy, Jabil
(813) 415-1116
michelle_smith@jabil.com
Investor Contact
Adam Berry
VP Investor Relations, Jabil
(727) 803-5772
adam_berry@jabil.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom